Dermata Therapeutics (DRMA) Price & Analysis

Compare

125 Followers

DRMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.59 - $23.70

Previous CloseN/A

Volume28.34K

Average Volume (3M)36.32K

Market Cap

$3.54M

Enterprise Value-$475.87K

Total Cash (Recent Filing)$6.48M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Nov 18, 2025

EPS Estimate

-1.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.66

Shares Outstanding681,557

10 Day Avg. Volume56,942

30 Day Avg. Volume36,321

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.13

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.05

Forecast

1Y Price Target

$10.00

Price Target Upside92.68% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessXYNGARI met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once-weekly treatment.

Clinical UtilityThe additional positive P3 data reinforces belief in the efficacy of XYNGARI and gives additional confidence in the product's clinical utility ahead of the upcoming STAR-2 trial.

Regulatory StrategyThe strategic shift toward the FDA OTC monograph pathway is seen as a prudent move that should reduce time to market, regulatory hurdles, and capital requirements for commercializing Spongilla technology.

Bears Say

Capital RequirementsThe company is pre-revenue and is expected to require a capital raise before the end of 2025.

Funding NeedsThe company will need to raise substantial additional capital or enter into a strategic partnership or licensing agreements to support a second Phase 3 trial.

Share DilutionExpected share dilution from anticipated capital raises to support clinical initiatives has led to a lowered 12-month price target to $10.00.

Dermata Therapeutics News

Dermata Therapeutics announces strategic pivot to OTC skin care treatments

Dermata Therapeutics (DRMA) announced a strategic pivot to prioritize the development and distribution of over-the-counter pharmaceutical dermatology focused...

19d ago

DRMA

Dermata Therapeutics withdraws IND application for XYNGARI

As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug...

19d ago

DRMA

Dermata Therapeutics Presents Promising Phase 3 Trial Results

Dermata Therapeutics ( ($DRMA) ) has provided an update. On September 17, 2025, Dermata Therapeutics presented clinical data...

12d ago

DRMA

Dermata Shifts Focus to Over-the-Counter Dermatology

Dermata Therapeutics ( ($DRMA) ) just unveiled an update. On September 10, 2025, Dermata Therapeutics announced a strategic...

19d ago

DRMA

Dermata Therapeutics Regains Nasdaq Compliance by August 2025

The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On May 14, 2025, Dermata Therapeutics received...

1M ago

DRMA

Dermata Therapeutics price target lowered to $10 from $30 at Maxim

Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $10 from $30 and keeps a Buy...

1M ago

DRMA

Dermata Therapeutics Reports Positive Phase 3 Trial Results

An announcement from Dermata Therapeutics ( ($DRMA) ) is now available. Dermata Therapeutics announced positive results from its...

2M ago

DRMA

Dermata Therapeutics Inc trading halted, news pending

19:50 EDT Dermata Therapeutics (DRMA) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

DRMA

Dermata Therapeutics Announces Reverse Stock Split

The latest update is out from Dermata Therapeutics ( ($DRMA) ). On July 30, 2025, Dermata Therapeutics announced...

2M ago

DRMA

Dermata Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On July 15, 2025, Dermata Therapeutics held...

3M ago

DRMA

Dermata Therapeutics receives notice of grant of Australian patent

Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its DMT410 program for...

3M ago

DRMA

Dermata Faces Nasdaq Delisting Risk, Plans Stock Split

Dermata Therapeutics ( ($DRMA) ) has issued an announcement. On May 14, 2025, Dermata Therapeutics received a letter...

3M ago

DRMA

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

Dermata Therapeutics ( ($DRMA) ) has provided an update. On May 20, 2025, Dermata Therapeutics announced the initiation...

4M ago

DRMA

Dermata Therapeutics price target lowered to $3 from $6 at Maxim

Maxim analyst Anthony Vendetti lowered the firm’s price target on Dermata Therapeutics (DRMA) to $3 from $6 and...

4M ago

DRMA

DRMA FAQ

What was Dermata Therapeutics’s price range in the past 12 months?

Dermata Therapeutics lowest stock price was $4.59 and its highest was $23.70 in the past 12 months.

What is Dermata Therapeutics’s market cap?

Dermata Therapeutics’s market cap is $3.54M.

When is Dermata Therapeutics’s upcoming earnings report date?

Dermata Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 50 days.

How were Dermata Therapeutics’s earnings last quarter?

Dermata Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.66 earnings per share for the quarter, beating the consensus estimate of -$2.9 by $1.24.

Is Dermata Therapeutics overvalued?

According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dermata Therapeutics pay dividends?

Dermata Therapeutics does not currently pay dividends.

What is Dermata Therapeutics’s EPS estimate?

Dermata Therapeutics’s EPS estimate is -1.59.

How many shares outstanding does Dermata Therapeutics have?

Dermata Therapeutics has 681,557 shares outstanding.

What happened to Dermata Therapeutics’s price movement after its last earnings report?

Dermata Therapeutics reported an EPS of -$1.66 in its last earnings report, beating expectations of -$2.9. Following the earnings report the stock price went down -9.783%.

Which hedge fund is a major shareholder of Dermata Therapeutics?

Currently, no hedge funds are holding shares in DRMA

Dermata Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-231.27%

Trailing 12-Months

Asset Growth

26.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dermata Therapeutics

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Dermata Therapeutics (DRMA) Earnings & Revenues

Historic Earnings Reports

DRMA Stock 12 Month Forecast

Average Price Target

$10.00

▲(92.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","191":"$191","50.75":"$50.8","97.5":"$97.5","144.25":"$144.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,50.75,97.5,144.25,191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.78,6.104615384615385,6.429230769230769,6.753846153846154,7.078461538461538,7.403076923076923,7.727692307692308,8.052307692307693,8.376923076923077,8.701538461538462,9.026153846153846,9.350769230769231,9.675384615384615,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.78,6.104615384615385,6.429230769230769,6.753846153846154,7.078461538461538,7.403076923076923,7.727692307692308,8.052307692307693,8.376923076923077,8.701538461538462,9.026153846153846,9.350769230769231,9.675384615384615,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.78,6.104615384615385,6.429230769230769,6.753846153846154,7.078461538461538,7.403076923076923,7.727692307692308,8.052307692307693,8.376923076923077,8.701538461538462,9.026153846153846,9.350769230769231,9.675384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":190.5,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.62,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >